ARMP
$9.99+0.31 (+3.22%)
Armata Pharmaceuticals, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacte...
Recent News
H.C. Wainwright Reaffirms Buy on Armata Pharmaceuticals, Inc. (ARMP) After FDA Nod
Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the 12 Most Promising Small-Cap Stocks According to Wall Street Analysts. Armata Pharmaceuticals, Inc. (NYSEAM:ARMP) is among the most promising stocks. On February 23, 2026, H.C. Wainwright increased the price target for ARMP from $9.00 to $15.00 and kept a Buy rating on the shares. The modification comes after […]
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
Armata Pharmaceuticals (ARMP) delivered earnings and revenue surprises of 0.00% and -16.01%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Misses Q3 Earnings and Revenue Estimates
Agenus (AGEN) delivered earnings and revenue surprises of -26.24% and -71.95%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Coherus Oncology (CHRS) Reports Q3 Loss, Lags Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -3.13% and -5.23%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Exact Sciences (EXAS) Q3 Earnings and Revenues Beat Estimates
Exact Sciences (EXAS) delivered earnings and revenue surprises of +84.62% and +4.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?